Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) have earned a consensus rating of “Moderate Buy” from the twenty-five research firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have given a hold rating, twenty-one have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $131.6250.

Several research firms have recently issued reports on KYMR. Wells Fargo & Company raised their price target on shares of Kymera Therapeutics from $116.00 to $151.00 and gave the company an “overweight” rating in a research note on Thursday, August 27th. B. Riley Financial increased their price objective on Kymera Therapeutics from $117.00 to $155.00 and gave the company a “buy” rating in a report on Monday, June 29th. Citigroup reaffirmed a “buy” rating on shares of Kymera Therapeutics in a research report on Thursday, August 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Friday, July 17th. Finally, Brookline Capital Markets reaffirmed a “buy” rating on shares of Kymera Therapeutics in a report on Monday, June 8th.

Insider Buying and Selling

In other news, Director Bvf Partners L. P/Il sold 1,578,800 shares of the firm’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $106.50, for a total transaction of $168,142,200.00. Following the completion of the transaction, the director directly owned 240,123 shares in the company, valued at $25,573,099.50. This trade represents a 86.80% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bruce Booth sold 467,878 shares of Kymera Therapeutics stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $110.29, for a total value of $51,602,264.62. Following the completion of the transaction, the director directly owned 472,267 shares in the company, valued at approximately $52,086,327.43. This represents a 49.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 3,362,132 shares of company stock valued at $365,904,088 over the last three months. 15.98% of the stock is owned by insiders.

Hedge Funds Weigh In On Kymera Therapeutics

A number of hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC lifted its holdings in Kymera Therapeutics by 27.5% in the second quarter. GAMMA Investing LLC now owns 454 shares of the company’s stock valued at $52,000 after buying an additional 98 shares during the period. Larson Financial Group LLC raised its position in shares of Kymera Therapeutics by 36.9% in the 4th quarter. Larson Financial Group LLC now owns 1,064 shares of the company’s stock worth $83,000 after acquiring an additional 287 shares in the last quarter. PNC Financial Services Group Inc. raised its position in shares of Kymera Therapeutics by 56.3% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,285 shares of the company’s stock worth $107,000 after acquiring an additional 463 shares in the last quarter. Nykredit A S acquired a new position in shares of Kymera Therapeutics in the 2nd quarter valued at about $207,000. Finally, DMC Group LLC acquired a new position in shares of Kymera Therapeutics in the 2nd quarter valued at about $229,000.

Kymera Therapeutics Price Performance

Kymera Therapeutics stock opened at $117.75 on Tuesday. The business has a 50 day moving average of $114.36 and a 200-day moving average of $96.85. Kymera Therapeutics has a 1 year low of $47.90 and a 1 year high of $130.05. The company has a market capitalization of $9.79 billion, a P/E ratio of -36.34 and a beta of 1.96.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Wednesday, August 5th. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.09. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. The business had revenue of $65.00 million for the quarter, compared to the consensus estimate of $32.78 million. During the same period last year, the company earned ($0.95) EPS. The firm’s revenue was up 465.2% compared to the same quarter last year. Equities analysts anticipate that Kymera Therapeutics will post -3.83 EPS for the current year.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that selectively remove disease-causing proteins from cells. The company’s approach is based on targeted protein degradation, which uses small-molecule degraders to direct unwanted proteins to the cell’s natural disposal system rather than simply blocking their activity.

Kymera’s research and development activities are supported by its proprietary Pegasus platform, which is designed to identify degradable proteins and create drug candidates against them.